An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis [IPF] and progressive pulmonary fibrosis [PPF] [FIBRONEERâ„¢-ON] (NCT06238622)

FIBRONEERâ„¢-ON

This trial is Currently recruiting
Registration number NCT06238622

Program & service

This trial is being run with the Heart & Lung service, and as part of the Respiratory program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Associate Professor Ian Glaspole

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.